MARKET

ANIK

ANIK

Anika
NASDAQ

Real-time Quotes | Nasdaq Last Sale

41.98
+1.20
+2.94%
After Hours: 41.98 0 0.00% 16:00 05/07 EDT
OPEN
40.80
PREV CLOSE
40.78
HIGH
42.33
LOW
40.45
VOLUME
163.44K
TURNOVER
--
52 WEEK HIGH
47.48
52 WEEK LOW
27.54
MARKET CAP
603.11M
P/E (TTM)
-24.8874
1D
5D
1M
3M
1Y
5Y
Soft Tissue Repair Market Latest Technology Analysis 2021-2025 by Upcoming Trends, Top Company Analysis with COVID-19 Impact, Such as - Atrium Medical, Baxter, BioHorizons, Anika Therapeutics, C.R. Bard
May 07, 2021 (The Expresswire) -- Final Report will add the analysis of the impact of COVID-19 on this industry. Global “Soft Tissue Repair Market” 2020-2025...
The Express Wire · 16h ago
Viscosupplementation Market Share Analysis with Demand Status 2021 | Latest Technological Advancement, Industry Trends, Competitive Landscape, Explosive Factors of Revenue by Key Vendors Size Forecast Analysis 2026
May 07, 2021 (The Expresswire) -- The Viscosupplementation industry has undergone many changes in recent years and expects numerous variations in the coming...
The Express Wire · 16h ago
Anika Therapeutics (ANIK) Surpasses Q1 Earnings and Revenue Estimates
Zacks · 20h ago
8-K: Anika Therapeutics, Inc.
(EDGAR Online via COMTEX) -- 0000898437 False 0000898437 2021-05-06 2021-05-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 1d ago
Anika Therapeutics Q1 EPS $0.06 Beats $(0.12) Estimate, Sales $34.30M Beat $32.20M Estimate
Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.12) by 150 percent. This is a 86.67 percent decrease over earnings of $0.45 per share from
Benzinga · 1d ago
Anika Therapeutics EPS beats by $0.10, beats on revenue
Anika Therapeutics (ANIK): Q1 Non-GAAP EPS of $0.06 beats by $0.10; GAAP EPS of $0.20 beats by $0.33.Revenue of $34.29M (-3.1% Y/Y) beats by $2.09M.Press Release
Seekingalpha · 1d ago
Anika Reports First Quarter 2021 Financial Results
BEDFORD, May 06, 2021 (GLOBE NEWSWIRE via COMTEX) -- Revenue lower by 3% versus pre-COVID in prior yearJoint Preservation revenue up 55% as transformative...
GlobeNewswire · 1d ago
Anika Therapeutics, Inc. to Host Earnings Call
May 06, 2021 (ACCESSWIRE via COMTEX) -- NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Anika Therapeutics, Inc. (NASDAQ:ANIK) will be discussing their earnings...
ACCESSWIRE · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANIK. Analyze the recent business situations of Anika through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANIK stock price target is 48.00 with a high estimate of 52.00 and a low estimate of 44.00.
EPS
Institutional Holdings
Institutions: 278
Institutional Holdings: 15.06M
% Owned: 104.83%
Shares Outstanding: 14.37M
TypeInstitutionsShares
Increased
41
584.14K
New
23
187.69K
Decreased
69
633.98K
Sold Out
16
192.86K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.86%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
President/Chief Executive Officer/Director
Cheryl Blanchard
Chief Financial Officer/Executive Vice President/Treasurer
Michael Levitz
Executive Vice President/General Counsel/Secretary
David Colleran
Executive Vice President/Director of Human Resources
Thomas Finnerty
Executive Vice President
James Loerop
Independent Director
John Henneman
Independent Director
Raymond Land
Independent Director
Glenn Larsen
Independent Director
Jeffrey Thompson
Independent Director
Stephen Richard
Independent Director
Jeffery Thompson
Independent Director
Susan Vogt
No Data
About ANIK
Anika Therapeutics, Inc. is a joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care. It partners with physicians and develops minimally invasive products. It focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. Its product categories include joint pain management therapies, orthopedic joint preservation and restoration care, and other. The joint pain management therapies offer injectable viscosupplement products that provide pain relief from osteoarthritis conditions and its products include MONOVISC, ORTHOVISC, CINGAL and HYVISC. The Company's orthopedic joint preservation and restoration care products include HYALOFAST and TACTOSET. It also offers a line of surgical implant and instrumentation solutions that are used by surgeons to repair and reconstruct damaged ligaments and tendons due to sports injuries, trauma and disease.

Webull offers kinds of Anika Therapeutics Inc stock information, including NASDAQ:ANIK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIK stock methods without spending real money on the virtual paper trading platform.